CSF3, colony stimulating factor 3, 1440

N. diseases: 687; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0030193
Disease: Pain
Pain
0.380 Biomarker phenotype BEFREE The severity of G-CSF-related musculoskeletal pain was increased on the second and third days of treatment. 31127438 2020
CUI: C0030193
Disease: Pain
Pain
0.380 Biomarker phenotype BEFREE Treatment increased spleen size (before G-CSF, 47%, on treatment on G-CSF 76%), and splenomegaly was the dose-limiting adverse effect of treatment (pain and early satiety). 30451720 2019
CUI: C0030193
Disease: Pain
Pain
0.380 Biomarker phenotype BEFREE Therapy with granulocyte colony-stimulating factor (G-CSF) is known by the pain caused as its main side effect. 30945072 2019
CUI: C0030193
Disease: Pain
Pain
0.380 Biomarker phenotype BEFREE The study group or chemotherapy cycles utilising long-acting G-CSF had significantly fewer utilisations and doses of short-acting G-CSF; clinical visits; CBC tests; and incidences of FN and myelosuppression; and less G-CSF-associated pain. 31467066 2019
CUI: C0030193
Disease: Pain
Pain
0.380 Biomarker phenotype BEFREE Patients receiving reduced-dose filgrastim reported significantly lower peak pain values in a numeric analogue scale (P = .01), and the costs were significantly lower than in patients undergoing standard-dose chemomobilization (P = .001). 29246820 2018
CUI: C0030193
Disease: Pain
Pain
0.380 AlteredExpression phenotype BEFREE In previous studies that have profiled gene expression in patients with complex regional pain syndrome (CRPS), the expression of granulocyte colony-stimulating factor 3 receptor (G‑CSFR) was elevated, as were a number of pain‑associated genes. 28656207 2017
CUI: C0030193
Disease: Pain
Pain
0.380 Biomarker phenotype BEFREE These data suggest that G-CSFR/G-CSF targeting may be a safe therapeutic strategy for arthritis and other inflammatory conditions, particularly those in which pain is important, as well as for inflammatory pain per se. 28320832 2017
CUI: C0030193
Disease: Pain
Pain
0.380 GeneticVariation phenotype BEFREE We serendipitously observed dramatic relief of pain in several patients with painful DN receiving granulocyte-colony stimulating factor (G-CSF). 26190836 2015
CUI: C0030193
Disease: Pain
Pain
0.380 Biomarker phenotype CTD_human Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing. 10864982 2000
CUI: C0030193
Disease: Pain
Pain
0.380 Biomarker phenotype CTD_human Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. 8622042 1996
CUI: C0030193
Disease: Pain
Pain
0.380 Biomarker phenotype CTD_human Astemizole in the treatment of granulocyte colony-stimulating factor-induced bone pain. 7541186 1995